Fisher Asset Management LLC Sells 300,630 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Fisher Asset Management LLC lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 9.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,884,569 shares of the biotechnology company’s stock after selling 300,630 shares during the quarter. Fisher Asset Management LLC’s holdings in BioCryst Pharmaceuticals were worth $17,279,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of BCRX. Quarry LP bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $54,000. Tower Research Capital LLC TRC increased its stake in shares of BioCryst Pharmaceuticals by 131.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 5,912 shares in the last quarter. JGP Global Gestao de Recursos Ltda. bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $64,000. MA Private Wealth bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $76,000. Finally, Counterweight Ventures LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $81,000. Institutional investors own 85.88% of the company’s stock.

Insiders Place Their Bets

In related news, insider Helen M. Thackray purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were bought at an average cost of $5.86 per share, with a total value of $175,800.00. Following the acquisition, the insider now owns 272,139 shares of the company’s stock, valued at $1,594,734.54. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Machelle Sanders sold 4,689 shares of the business’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $6.00, for a total value of $28,134.00. Following the transaction, the director now directly owns 27,742 shares of the company’s stock, valued at approximately $166,452. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Helen M. Thackray purchased 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was bought at an average cost of $5.86 per share, for a total transaction of $175,800.00. Following the completion of the acquisition, the insider now directly owns 272,139 shares in the company, valued at approximately $1,594,734.54. The disclosure for this purchase can be found here. Insiders have bought 103,601 shares of company stock valued at $596,338 in the last three months. 4.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BCRX. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 7th. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Finally, JMP Securities lifted their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, May 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $14.00.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $6.00 on Wednesday. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -5.61 and a beta of 1.87. The firm’s fifty day moving average price is $5.55 and its two-hundred day moving average price is $5.61. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $7.95.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $92.80 million for the quarter, compared to analysts’ expectations of $85.62 million. BioCryst Pharmaceuticals’s revenue was up 34.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.28) earnings per share. As a group, equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.